INS and Hyperglycemia: STZ enters the cytoplasm of β-cells in the pancreas [28] via glucose transporter-2 and reduces insulin secretion through cell toxicity [29–31] and thus, the STZ-injected animals develop hyperglycemia, resembling the conditions seen in type I diabetes.